Bio-Rad Laboratories, Inc. is scheduled to announce its earnings for the fourth quarter of 2025 on February 12, 2026, after markets close. Analysts predict the company will report earnings of $2.57 per share and total revenues of $694.6 million for the quarter. Investors and analysts can access the earnings summary and listen to the conference call at 5:00 PM ET on the same day.
Current Financial Performance
Shares of Bio-Rad, traded under the ticker symbol NYSE:BIO, opened at $294.66 on Tuesday. The company currently maintains a strong liquidity position, with a quick ratio of 3.94 and a current ratio of 5.44. Its debt-to-equity ratio stands at 0.18, indicating relatively low leverage. Bio-Rad has a 50-day moving average price of $308.14 and a 200-day moving average price of $300.66. Over the past year, the stock has fluctuated between a low of $211.43 and a high of $343.12. The company’s market capitalization is approximately $7.95 billion.
Analyst Ratings and Price Targets
Recent evaluations from several research analysts have offered varying ratings for Bio-Rad stock. On October 30, Citigroup raised its price target from $350.00 to $375.00, maintaining a “buy” rating. Similarly, Wells Fargo & Company adjusted its price objective from $265.00 to $340.00, issuing an “equal weight” rating. Analysts from Wall Street Zen upgraded Bio-Rad from a “hold” to a “buy” rating on January 10. In contrast, Weiss Ratings reaffirmed a “sell (d-)” rating in late December. Overall, the stock holds an average rating of “Hold” with a price target of $358.50, according to data from MarketBeat.com.
Institutional investors have also been active in trading Bio-Rad shares. Geneos Wealth Management Inc. increased its stake by 115.2% in the second quarter, now holding 142 shares. Quarry LP and CIBC Private Wealth Group LLC also expanded their holdings during the third quarter, with increases of 131.5% and 241.2%, respectively. Notably, hedge funds and institutional investors collectively own 65.24% of the company’s stock.
Bio-Rad Laboratories operates as a global provider of life science research and clinical diagnostic products. The company is divided into two primary business segments: Life Science and Clinical Diagnostics. The Life Science segment offers instruments, reagents, and consumables for various applications, including protein analysis and gene expression. The Clinical Diagnostics segment supplies quality control products and molecular diagnostic assays for blood screening and infectious disease testing.
Founded in 1952 by David and Alice Schwartz, Bio-Rad is headquartered in Hercules, California, and has expanded its operations across the Americas, Europe, and Asia-Pacific. As the earnings report approaches, the market will be closely monitoring Bio-Rad’s performance and future prospects.
